AbbVie combines high yield, strong growth from Rinvoq and Skyrizi, and a solid pipeline to support dividends and returns.

However, the pharma company has prepared two other immunology drugs to compensate -- and together, they may even beat Humira. And you're not the only one. So far this year, AbbVie shares have ...

AbbVie's Humira, a blockbuster drug used to treat numerous autoimmune conditions, has been an exceptionally lucrative asset, generating over $20 billion at the height of its annual sales.

U.S. Humira sales fell 40% year over year during the first three months of 2024, to about $1.8 billion, as biosimilar copycats put pressure on AbbVie’s top-selling drug, the company said Friday ...

“AbbVie and Humira showed other companies what it was ... has never had to pay more than $5 for a refill of the drug because her employer’s insurance plan picks up most of the tab.

Experts — and even Humira's own manufacturer, AbbVie — are confident this new competition will soon cut spending on the drug nearly in half. Those savings would mostly benefit insurers and ...

AbbVie's best-selling product lost patent-protected market exclusivity in the U.S. this year. Competition with lower-cost biosimilar versions of Humira is expected to shrink earnings for at least ...

Humira, AbbVie’s blockbuster immunology drug, is finally facing competition from copycats. It really needs its other drugs to start chipping in. Yet newer immunology drugs Skyrizi and Rinvoq ...